147 related articles for article (PubMed ID: 38280386)
1. What are the Changes in 2023 for Access to Advanced Therapy Medicinal Products (ATMPs) in France?
Bartos B
Eur J Health Law; 2024 Jan; 31(2):187-208. PubMed ID: 38280386
[TBL] [Abstract][Full Text] [Related]
2. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
3. Funding breakthrough therapies: A systematic review and recommendation.
Hanna E; Toumi M; Dussart C; Borissov B; Dabbous O; Badora K; Auquier P
Health Policy; 2018 Mar; 122(3):217-229. PubMed ID: 29223847
[TBL] [Abstract][Full Text] [Related]
4. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
5. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
[TBL] [Abstract][Full Text] [Related]
6. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
7. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
8. [The French medecine pricing committee].
Giorgi D
Ann Pharm Fr; 2017 Sep; 75(5):373-384. PubMed ID: 28583317
[TBL] [Abstract][Full Text] [Related]
9. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
11. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
12. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities for access to Advanced Therapy Medicinal Products in Brazil.
Sachetti CG; Barbosa A; de Carvalho ACC; Araujo DV; da Silva EN
Cytotherapy; 2024 Mar; ():. PubMed ID: 38639672
[TBL] [Abstract][Full Text] [Related]
14. Managing access to advanced therapy medicinal products: Challenges for NHS Wales.
Champion AR; Lewis S; Davies S; Hughes DA
Br J Clin Pharmacol; 2021 Jun; 87(6):2444-2449. PubMed ID: 32495405
[TBL] [Abstract][Full Text] [Related]
15. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012.
Dervaux B; Baseilhac E; Fagon JY; ; Ameye V; Angot P; Audry A; Becquemont L; Borel T; Cazeneuve B; Courtois J; Detournay B; Favre P; Granger M; Josseran A; Lassale C; Louvet O; Pinson J; de Pouvourville G; Rochaix L; Rumeau-Pichon C; de Saab R; Schwarzinger M; Sun A
Therapie; 2013; 68(4):253-63. PubMed ID: 23981264
[TBL] [Abstract][Full Text] [Related]
16. Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions.
Li H; Liu GG; Wu J; Wu JH; Dong CH; Hu SL
Value Health Reg Issues; 2018 May; 15():133-137. PubMed ID: 29705645
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
18. Pricing and reimbursement of pharmaceuticals in Belgium.
Annemans L; Crott R; De Clercq H; Huybrechts M; Peys F; Robays H; Steens I; Vanschoubroek K; Winderickx P
Pharmacoeconomics; 1997 Mar; 11(3):203-9. PubMed ID: 10165309
[TBL] [Abstract][Full Text] [Related]
19. Is the price right? Paying for value today to get more value tomorrow.
Ramagopalan SV; Diaz J; Mitchell G; Garrison LP; Kolchinsky P
BMC Med; 2024 Jan; 22(1):45. PubMed ID: 38287326
[TBL] [Abstract][Full Text] [Related]
20. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
